<DOC>
	<DOC>NCT01431638</DOC>
	<brief_summary>This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.</brief_summary>
	<brief_title>Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Gouty</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Compliance and completion of the canakinumab PFS core study Unchanged significant clinical medical history from entry into core study Exclusion criteria: Physician judgment of unsuitability for the study Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gout</keyword>
	<keyword>arthritis</keyword>
	<keyword>gout flare</keyword>
	<keyword>acute gout</keyword>
	<keyword>gouty</keyword>
	<keyword>rheumatic disease</keyword>
	<keyword>uric acid</keyword>
	<keyword>podagra</keyword>
</DOC>